ARCTURUS THERAPEUTICS HOLDINGS INC. Current Liabilities
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) had Current Liabilities of $33.54 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $33.54M.
- 2026-03-31: Liabilities, Current $34.37M.
- 2025-12-31: Liabilities, Current $36.38M.
- 2025-09-30: Liabilities, Current $31.70M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $33.54M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $34.37M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $36.38M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $31.70M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $46.52M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $49.41M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $65.49M 10-K · filed 2026-03-03 |
| 2024-09-30 | $69.46M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $91.72M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $115.43M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $81.99M 10-K · filed 2025-03-06 |
| 2023-09-30 | $87.68M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $90.34M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $90.13M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $126.98M 10-K · filed 2024-03-14 |
| 2022-09-30 | $75.85M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $92.74M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $107.31M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $99.54M 10-K · filed 2023-03-29 |
| 2021-09-30 | $118.24M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $70.77M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $53.33M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $49.52M 10-K · filed 2022-03-01 |
| 2020-09-30 | $28.01M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $23.05M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $21.65M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $21.32M 10-K · filed 2021-03-01 |
| 2019-09-30 | $21.69M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $16.41M 10-Q · filed 2019-08-14 |
| 2018-12-31 | $12.58M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |